VERICEL CORPORATION Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $2.32M, a 75.61% increase year-over-year.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.31M, a 85.73% decline year-over-year.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.10M, a 79.84% decline year-over-year.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $1.32M, a 67.16% decline year-over-year.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for fiscal 2025 was $12.48M, a 46.04% decline from fiscal 2024.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for fiscal 2024 was $23.13M, a 388.18% increase from fiscal 2023.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for fiscal 2023 was $4.74M, a 97.29% increase from fiscal 2022.
- VERICEL CORPORATION stock issued during period, value, stock options exercised for fiscal 2022 was $2.40M, a 75.82% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $2.32M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $1.31M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $12.48M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.32M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $9.16M 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $23.13M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $5.44M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $4.02M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $6.78M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $4.74M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $787.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $889.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $2.01M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $2.40M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $498.00K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $428.00K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $1.16M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $9.93M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $1.68M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $3.53M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $3.53M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $5.58M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $500.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $696.00K 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $196.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $4.35M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $1.43M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $850.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $780.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $3.71M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $952.00K 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $964.00K 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $851.00K 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $608.00K 10-K · filed 2020-02-25 | |
| 2016-12-31 | $120.00K 10-K · filed 2019-02-26 | |
| 2015-12-31 | $11.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |